Log in
Enquire now
‌

US Patent 11661410 Tricyclic compounds as histone methyltransferase inhibitors

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Global Blood Therapeutics
Global Blood Therapeutics
0
Current Assignee
Global Blood Therapeutics
Global Blood Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
116614100
Date of Patent
May 30, 2023
0
Patent Application Number
166390510
Date Filed
August 13, 2018
0
Patent Citations
‌
US Patent 11254651 Histone methyltransferase inhibitors
0
Patent Primary Examiner
‌
Bruck Kifle
0
CPC Code
‌
C07D 405/14
0
‌
C07D 219/00
0
‌
C07D 221/06
0
‌
C07D 401/12
0
‌
C07D 413/12
0
‌
C07D 471/04
0
‌
C07D 471/08
0
‌
C07D 491/044
0
...

The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11661410 Tricyclic compounds as histone methyltransferase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.